Lexaria Bioscience
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2004-01-01
- Employees
- 5
- Market Cap
- -
- Introduction
Lexaria Bioscience Corp. is a biotechnology company, which engages in the provision of active pharmaceutical ingredients through its DehydraTECH drug delivery technology. Its products can be used with APIs fat-soluble vitamins, non-steroidal anti-inflammatory drugs (NSAIDs) pain medications, hormones, phosphodiesterase inhibitors, antivirals, nicotine and its analogs, and all cannabinoids including tetrahydrocannabinol (THC) for therapeutic indications, as well as hypertension, SARS-CoV-2/COVID-19, and HIV/AIDS. It operates through the following segments: IP Licensing, B2B Product, Research and Development, and Corporate. The company was founded on December 9, 2004 and is headquartered in Kelowna, Canada.
Clinical Trials
1
Trial Phases
1 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials
Comparison of the Safety, Efficacy and Pharmacokinetics of DehydraTECH -CBD and DehydraTECH-GLP1 Agonists Alone or in Combination, in Overweight or Obese, Pre- and Type 2 Diabetic Participants
- Conditions
- Type2diabetes
- Interventions
- Drug: Arm 1 - DehydraTECH-CBD aloneDrug: Arm 2 - DehydraTECH-semaglutide aloneDrug: Arm 3 - DehydraTECH-CBD in combination with DehydraTECH-semaglutideDrug: Arm 4 - Rybelsus medication (semaglutide) aloneDrug: Arm 5- Tirzepatide
- First Posted Date
- 2024-10-18
- Last Posted Date
- 2025-07-11
- Lead Sponsor
- Lexaria Bioscience Corp.
- Target Recruit Count
- 148
- Registration Number
- NCT06648031
- Locations
- 🇦🇺
Canopy Clinical Sutherland, Miranda, New South Wales, Australia
🇦🇺Canopy Clinical Wollongong, Wollongong, New South Wales, Australia
🇦🇺Paratus Clinical Pty Ltd, Blacktown Trial Clinic, Blacktown, New South Wales, Australia
News
Lexaria Bioscience Reaches 50-Patent Milestone with New Epilepsy and Nicotine Delivery Patents
Lexaria Bioscience Corp. has achieved a significant intellectual property milestone by reaching 50 patents worldwide, including two new international patents for epilepsy treatment and nicotine delivery applications.
Lexaria's Oral Tirzepatide Formulation Shows Reduced Side Effects, Comparable Efficacy to Injected Zepbound in Early Study
Lexaria Bioscience's oral DehydraTECH-tirzepatide demonstrated a 47% reduction in adverse events compared to injected Zepbound in a recent human study.
Lexaria Bioscience Receives FDA Clearance for Phase 1b Hypertension Trial of DehydraTECH-CBD
Lexaria Bioscience has received FDA clearance for its HYPER-H23-1 Phase 1b clinical trial to evaluate DehydraTECH-CBD in patients with stage 1 or 2 hypertension.
Lexaria Bioscience Initiates Phase 1b Study Evaluating DehydraTECH-Enhanced GLP-1 Drugs
Lexaria Bioscience has begun dosing in its Phase 1b study, GLP-1-H24-4, to assess its DehydraTECH technology's impact on GLP-1 drug safety and efficacy.
Lexaria's DehydraTECH GLP-1 Study Receives Ethics Board Approval, Aims to Enhance Oral Delivery of Diabetes and Weight Loss Drugs
Lexaria Bioscience has received ethics board approval for its Phase 1b study evaluating DehydraTECH-processed GLP-1 drugs for diabetes and weight loss.
Lexaria's Oral Tirzepatide Pilot Study Begins Dosing, Evaluating DehydraTECH Delivery
Lexaria Bioscience has initiated dosing in a human pilot study evaluating an oral formulation of tirzepatide, processed with their DehydraTECH technology.